Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Improvements in Quality of Life and Clinical Efficacy in Two Pivotal Phase 3 Trials

Linda Stein Gold; Christopher Em Griffiths; Anna M. Tallman; Philip M. Brown; Mark Lebwohl

doi:10.25251/skin.6.supp.53

Back

Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Improvements in Quality of Life and Clinical Efficacy in Two Pivotal Phase 3 Trials

Article 2022 en

Related publications

Article2023

Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Improvements in Quality of Life and Clinical Efficacy in Two Pivotal Phase 3 Trials

Linda Stein Gold, Christopher Em Griffiths, Anna M. Tallman, Philip Marshall Brown, Mark Lebwohl

Article2014

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

Richard G. Langley, Boni E. Elewski, Mark Lebwohl, Kristian Reich, Christopher Em Griffiths, Kim Papp, L. Puig, Hidemi Nakagawa, Lynda Spelman, Bárður Sigurgeirsson, Enrique Rivas, Tsen‐Fang Tsai, Norman Wasel, Stephen K. Tyring, Thomas Salko, Isabelle Hampele, Marianne Notter, Alexander Karpov, Silvia Helou, C. Papavassilis

Article2017

Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)

Andrew Blauvelt, Kim Papp, Christopher Em Griffiths, L. Puig, Jamie Weisman, Yves Dutronc, Lisa Farmer Kerr, Dapo Ilo, Lotus Mallbris, Matthias Augustin

Article2020

Clinical efficacy and safety of secukinumab in patients with psoriasis and comorbidities: pooled analysis of 4 phase 3 clinical trials

Alice B. Gottlieb, Jashin J. Wu, Christopher Em Griffiths, Kwaku Marfo, Elisa Muscianisi, Xiangyi Meng, Jennifer Frueh, Mark Lebwohl

Article1997

Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress

Dónal G. Fortune, Chris J. Main, T.M. O'SULLIVAN, Christopher Em Griffiths

Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Improvements in Quality of Life and Clinical Efficacy in Two Pivotal Phase 3 Trials

Abstract

Discussion(0)

Related publications

Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Improvements in Quality of Life and Clinical Efficacy in Two Pivotal Phase 3 Trials

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)

Clinical efficacy and safety of secukinumab in patients with psoriasis and comorbidities: pooled analysis of 4 phase 3 clinical trials

Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress